Aplastic Anemia (AA) & MDS Overlap Syndrome: Why PNH Clones Emerge in Bone Marrow Failure
Nothing confuses newly diagnosed patients more than being told: "You have Severe Aplastic Anemia, and your flow cytometry also shows a 12% PNH clone." How can one person simultaneously have two ultra-rare blood diseases with incidences of 2 per million?
The answer is that Acquired Aplastic Anemia (AA), Paroxysmal Nocturnal Hemoglobinuria (PNH), and Hypoplastic Myelodysplastic Syndrome (hMDS) are not separate coincidences: they are three intersecting manifestations of an autoimmune bone marrow attack.
Between 40% and 50% of patients with acquired aplastic anemia (AA) and 15% to 20% with hypoplastic myelodysplastic syndrome (MDS) harbor a GPI-deficient PNH clone. Autoreactive cytotoxic T-lymphocytes attack normal stem cells via GPI-linked targets while sparing PIGA-mutant stem cells, allowing the PNH clone to expand and repopulate the bone marrow.
Why Does a PIGA Mutation Alone Never Cause PNH Without Bone Marrow Autoimmunity?
Healthy human donors often carry tiny, silent PIGA-mutated stem cells (<0.005%) that never expand. A PIGA mutation confers zero intrinsic proliferative advantage (unlike a leukemic oncogene). For a single PNH stem cell to take over 50% to 95% of a person's bone marrow, a two-step evolutionary selection must occur:
- Step 1: Somatic PIGA Mutation Creates a "Stealth" Stem Cell. An X-linked somatic mutation in the PIGA (phosphatidylinositol glycan anchor biosynthesis class A) gene halts the synthesis of GPI anchors on the surface of a hematopoietic stem cell. Because PIGA sits on the X chromosome, a single hit in men (or a single hit on the active X chromosome in women) completely abolishes all ~150 GPI-anchored surface proteins.
- Step 2: Autoimmune T-Cell Attack Destroys Normal GPI+ Stem Cells (Aplastic Anemia). In acquired aplastic anemia, autoreactive CD8+ cytotoxic T-cells and NK cells attack normal hematopoietic stem cells, often recognizing glycolipid antigens presented by CD1d or engagements requiring GPI-linked co-receptors (such as ULBP1/2/3 ligands for NKG2D). Because the PIGA-mutant stem cell lacks GPI-anchored surface targets, it is invisible to the autoimmune attack.
- Clonal Expansion During Marrow Recovery: As normal stem cells are wiped out (causing aplastic anemia pancytopenia), the surviving GPI-deficient stem cell divides to refill the empty marrow space. When the clone grows past 10% to 50%, the patient transitions from pure aplastic anemia into hemolytic AA-PNH overlap.
| IPIG Clinical Subtype | Granulocyte Clone & Bone Marrow Biopsy | LDH & Reticulocyte Profile | Primary Treatment Strategy |
|---|---|---|---|
| 1. Classic Hemolytic PNH | Granulocyte clone 50% to 99%; Normocellular or hypercellular marrow with erythroid hyperplasia; normal karyotype. | LDH 3.0x to 10.0x ULN; high reticulocytes (>120 x 10^9/L); platelets >100 x 10^9/L. | COMPLEMENT INHIBITION Ravulizumab, Iptacopan, Pegcetacoplan, or Crovalimab. Immunosuppression not needed. |
| 2. PNH in the Setting of Bone Marrow Failure (Clinical AA-PNH Overlap) | Granulocyte clone 10% to 60%; Hypocellular marrow (<25%-30% cellularity) with thrombocytopenia/neutropenia. | LDH >=1.5x ULN (active intravascular hemolysis coexisting with marrow cytopenias). | CONCURRENT OR SEQUENTIAL THERAPY Treat severe marrow aplasia (hATG + CsA + Eltrombopag) AND control active hemolysis/thrombosis with a complement inhibitor. |
| 3. Subclinical PNH (AA or hMDS with Minor Clone) | Granulocyte clone 0.01% to <10%; Severe hypocellular AA marrow or hypoplastic MDS. | LDH <1.5x ULN (normal); low reticulocytes; no hemoglobinuria or PNH thrombosis. | TREAT AA/MDS ONLY · MONITOR CLONE Standard IST (ATG+CsA+Eltrombopag) or Allogeneic HSCT in young matched-sibling donors. Repeat flow cytometry every 6 months. |
Frequently Asked Hematology & Patient Questions
Direct, link-free clinical answers grounded in ASH, IPIG, and Phase 3 complement inhibitor trial evidence.
Can horse ATG, cyclosporine, and Promacta (eltrombopag) be given at the same time as Ultomiris or Soliris?
Yes. In patients who present with both severe bone marrow failure (severe thrombocytopenia/neutropenia from aplastic anemia) and active intravascular hemolysis or thrombosis from a large PNH clone, hematologists safely combine immunosuppressive therapy (ATG + cyclosporine + eltrombopag) with terminal C5 inhibition (ravulizumab or eculizumab). One clinical nuance is that polyclonal rabbit or horse ATG activates classical complement during infusion and can transiently lower free C5 inhibitor levels, so hematologists closely monitor LDH during the 4-day ATG course.
Clinical source: Kulasekararaj et al., Blood 2021 · See Complement Inhibitors.
Why did my PNH clone grow from 5% to 60% a year after my aplastic anemia responded to treatment?
As immunosuppressive therapy (ATG and cyclosporine) suppresses the autoimmune T-cell attack in the bone marrow, surviving stem cells proliferate rapidly to restore blood counts. If the PIGA-mutated stem cell pool had a head start during the aplastic phase, its progeny can expand disproportionately during hematopoietic recovery, converting subclinical AA-PNH into classic hemolytic PNH over 6 to 36 months.
Clinical source: Scheinberg et al., Ann Intern Med 2006.
Does an allogeneic bone marrow transplant (HSCT) cure both aplastic anemia and the PNH clone?
Yes. Allogeneic hematopoietic stem cell transplantation (HSCT) replaces the patient's entire defective hematopoietic stem cell pool with healthy donor stem cells, permanently eradicating both aplastic anemia and the PNH clone. Today, HSCT is primarily indicated for severe AA-PNH overlap in younger patients with a matched donor, clonal evolution to MDS/AML, or in health systems where lifelong complement inhibitors are inaccessible.
Clinical source: Peffault de Latour et al., Haematologica 2012 (EBMT Study) · See Global HSCT Centers.